Advances in Nitric Oxide and Cancer is a volume that serves to give the latest research on nitric oxide (NO) and cancer. More specifically, the volume reviews significant advances in the application of NO-mediated drugs. The volume explores nitric oxide and its relationship to cancer spanning from its roles in the pathogenesis, prognosis, gene and protein modifications, regulation of resistance to cytotoxics, and therapeutic applications. With chapters written by leading experts, the volume addresses the burgeoning interest in a rapidly advancing field and provides a valuable resource to scientists who have initiated research as well as clinical investigations in their laboratories on the various roles of NO and cancer.
قائمة المحتويات
Inflammation-associated Carcinogenesis Involved Interaction Between with i NOS/NO and WNT/beta-catenin.- NO and Genomic Stability.- Targeting Hyponitroxia in Cancer Therapy.- Mechanism of NO-dependent Regulation of Invasion and Metastasis.- NO Role in Protumorigenesis and Hypoxia.- Impacts of S-nitrosylation in Cancer.- S-nitrosylation of Cancer Cells.- Role of S-nitrosylation in Cancer Metastasis.- NO Immunity and Cancer.- Regulation of Anti-tumor Responses by NO.- NO Immune Modulation and Tumor Growth.- Role of NO in Chemo-immune Resistance.- Emerging Role of NO-mediated Therapeutics.- PDT and NO.- Regulation of Cell Death by NO.- Discovery and Development of RRx-001.- Nitric Oxide Coagulation and Cancer.- Neutrosphyngomyelinase 2.
عن المؤلف
Dr. Benjamin Bonavida is a professor at UCLA’s David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute’s SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He’s currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals.